Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
≥99% pour les flux de travail chromatographiques et analytiques sensibles nécessitant une interférence de ligne de base minimale.
Store at -20°C Expédition Ice chest + Ice pads. Consultez le COA spécifique au lot pour les spécifications exactes.
SDS, COA, fiche technique et fiche de spécifications disponibles au téléchargement. COA spécifique au lot accessible via la recherche par numéro de lot.
Cité dans 0 publications à comité de lecture couvrant la chromatographie, la synthèse organique et les réactions de couplage croisé.
Information
UT-34 UT-34 is a potent, selective and orally bioavailable second-generation androgen receptor (AR) pan antagonist and degrader with IC50 of 203.46 nM, 80.78 nM and 94.17 nM for wild-type, T877A and W741L AR, respectively. UT-34 is a potential next-generation therapeutic for enzalutamide-resistant prostate cancer.
Targets
AR-T877A (Cell-free assay); AR-W741L (Cell-free assay); AR-WT (Cell-free assay) 80.78 nM; 94.17 nM; 203.46 nM
In vitro
UT-34 inhibits the wild-type and LBD-mutant ARs comparably and inhibits the in vitro proliferation. UT-34 promotes a conformation that is distinct from the LBD-binding competitive antagonist enzalutamide and degrades the AR through the ubiquitin proteasome mechanism. UT-34 has a broad safety margin and exhibits no cross-reactivity with Gprotein-coupled receptor kinase and nuclear receptor family members.
In vivo
UT-34 inhibits the wild-type and LBD-mutant ARs comparably and inhibits the in vivo growth of enzalutamide-sensitive and -resistant prostate cancer xenografts. In preclinical models, UT-34 induces the regression of enzalutamide-resistant tumors at doses when the AR is degraded; but, at lower doses, when the AR is just antagonized, it inhibits, without shrinking, the tumors.
Cell Research(from reference)
Cell lines:LNCaP, PC-3, HEK-293, ZR-75-1, MDA-MB-453, VCaP, 22RV1, and COS7 cell lines
Concentrations:0.1 μM, 1 μM, 10 μM
Incubation Time:30 min, 24 h, 48 h
Document complet couvrant les dangers, la manipulation, le stockage et la conformité réglementaire.
<<<<<<< HEAD Télécharger la SDS → ======= Télécharger la SDS → >>>>>>> release248-p3Données qualité spécifiques au lot. Saisissez votre numéro de lot pour récupérer le COA exact.
Rechercher le COA →Résumé de référence rapide des spécifications et applications du produit.
Voir la fiche technique →Attributs de qualité complets et critères d'acceptation pour cette qualité.
Voir la fiche de spécifications →| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Article |
|---|---|---|---|
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 | |
| Certificate of Analysis | Feb 05, 2026 | U414245 |
| Solubilité | Solubility (25°C) In vitro DMSO: 71 mg/mL (199.28 mM); Ethanol: 71 mg/mL (199.28 mM); Water: Insoluble; |
|---|---|
| DMSO (mg/mL) Solubilité maximale | 71 |
| DMSO (mM) Solubilité maximale | 199.287057568698 |
| Eau (mg/mL) Solubilité maximale | <1 |
| Poids moléculaire | 356.270 g/mol |
| XLogP3 | 1.300 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 356.09 Da |
| Monoisotopic Mass | 356.09 Da |
| Topological Polar Surface Area | 90.900 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 549.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |